Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer

For endocrine-positive Her2 negative breast cancer patients at an early stage, the benefit of adding chemotherapy to adjuvant endocrine therapy is not still confirmed. Several genomic tests are available on the market but are very expensive. Therefore, there is the urgent need to explore novel relia...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanizzi, Annarita, Pomarico, Domenico, Rizzo, Alessandro, Bove, Samantha, Comes, Maria Colomba, Didonna, Vittorio, Giotta, Francesco, La Forgia, Daniele, Latorre, Agnese, Pastena, Maria Irene, Petruzzellis, Nicole, Rinaldi, Lucia, Tamborra, Pasquale, Zito, Alfredo, Lorusso, Vito, Massafra, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220052/
https://www.ncbi.nlm.nih.gov/pubmed/37237020
http://dx.doi.org/10.1038/s41598-023-35344-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220052/
https://www.ncbi.nlm.nih.gov/pubmed/37237020
http://dx.doi.org/10.1038/s41598-023-35344-9

Ejemplares similares